Advertisement

Impaired brain glucose metabolism in patients with Down Syndrome

  • O. Labudova
  • N. Cairns
  • E. Kitzmüller
  • G. Lubec
Conference paper

Summary

A series of impaired metabolic functions in Down Syndrome (DS) including glucose handling has been described. Recent information from positron emission tomography studies in DS patients and our finding of downregulated phosphoglucose isomerase (PGI) in fetal brain with DS by gene hunting using subtractive hybridization, made us investigate PGI, a key enzyme of glucose metabolism, in brain of patients with DS, Alzheimer’s disease (AD) and controls. PGI and phosphofructokinase (PFK) activities were determined in frontal, parietal, temporal, occipital lobe and cerebellum of 9 controls, 9 patients with DS and 9 patients with AD. PGI activity in DS brain was significantly decreased in frontal, temporal lobe and cerebellum, comparable to controls in parietal lobe and elevated in occipital lobe. Brain PGI activity of patients with AD was comparable to controls in all regions tested. PFK, a rate limiting enzyme of glucose metabolism, was comparable between all brain regions of all three groups. Data of this study confirm impaired glucose metabolism in DS proposed in literature and found by positron emission tomography (PET) studies. We show that changes in glucose handling in patients with AD as evaluated by PET studies are not supported by our data, although not contradictory, as determinants other than glucose metabolizing enzymes as e.g. vascular factors and glucose transport may account for these findings. Changes of downregulated PGI found by subtractive hybridization at the transcriptional level in fetal DS brain along with our findings in DS brain regions suggest a strong specific link between glucose metabolism and DS rather than AD.

Keywords

Down Syndrome Positron Emission Tomography Study Triose Phosphate Isomerase Impaired Glucose Metabolism Phosphoglucose Isomerase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anneren KG, Korenberg JR, Epstein CJ (1987) Phosphofructokinase activity in fibroblasts aneuploid for chromosome 2. Hum Genet 76: 63–65PubMedCrossRefGoogle Scholar
  2. Baikie AG, Loder PB, de Grouchy GC, Pitt DB (1965) Phosphohexokinase activity in erythrocytes in mongolism: another possible marker for chromosome 21. Lancet i: 412–414CrossRefGoogle Scholar
  3. Bartels H, Kruse K (1968) Enzymbestimmungen in Erythrozyten bei Kindern mit Down Syndrome. Humangenetik 5: 305–309PubMedCrossRefGoogle Scholar
  4. Beutler E (1975) Red cell metabolism. A manual of biochemical methods, 2nd ed. Grune and Stratton, NY, pp 40–45Google Scholar
  5. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254PubMedCrossRefGoogle Scholar
  6. Burger PC, Vogel FS (1973) The development of pathologic changes of Alzheimer’s disease and senile dementia in patients with Down’s syndrome. Am J Pathol 73: 457–476PubMedGoogle Scholar
  7. Dani A, Pietrini P, Furey M, McIntosh CL, Horwitz B, Freo U, Alexander GE, Schapiro MB (1996) Brain cognition and metabolism of Down syndrome adults in association with development of dementia. Neuroreport 7: 2933–2936PubMedCrossRefGoogle Scholar
  8. Epstein CJ (1986) The consequences of chromosomal imbalance. Principles, mechanisms, and models. Cambridge University Press, New YorkGoogle Scholar
  9. Epstein CJ (1992) Down Syndrome (Trisomy 21). In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease. McGraw Hill, New York, pp 749–794Google Scholar
  10. Haxby JV, Schapiro MB (1988) Longitudinal study of neuropsychological function in older adults with Down syndrome. In: Epstein C, Nadel L (eds) Down Syndrome and Alzheimer disease. Wiley-Liss, New York, pp 35–50Google Scholar
  11. Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI (1985) Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer’s disease. J Cereb Blood Flow Metab 5: 193–200PubMedCrossRefGoogle Scholar
  12. Hsia DY, Justice P, Smith GF, Dowben RM (1971) Down’s syndrome. A critical review of the biochemical and immunological data. Am J Dis Child 121: 153–163PubMedGoogle Scholar
  13. Katz LA (1996) Transkingdom transfer of the phosphoglucose isomerase gene. J Mol Evol 43: 453–459PubMedCrossRefGoogle Scholar
  14. Labudova O, Lubec G (1998) cAMP upregulates the transposable element mys-1: a possible link between signaling and mobile DNA. Life Sci 62: 431–437PubMedCrossRefGoogle Scholar
  15. Lai F, Williams RS (1989) A prospective study of Alzheimer’s disease in Down syndrome. Arch Neurol 46: 849–853PubMedCrossRefGoogle Scholar
  16. Layzer RB, Epstein CJ (1972) Phosphofructokinase and chromosome 21. Am J Hum Genet 24: 533–543PubMedGoogle Scholar
  17. Mirra SS, Heyman A, McKeel D, Sumi S, Crain BJ (1991) The consortium to establish a registry for Alzheimer disease (CERAD). II. Standardisation of the neuropathologi-cal assessment of Alzheimer’s disease. Neurology 41: 479–486PubMedCrossRefGoogle Scholar
  18. Pash J, Smithgall T, Bustin M (1991) Chromosomal protein HMG — 14 is overexpressed in Down syndrome. Exp Cell Res 193: 232–236PubMedCrossRefGoogle Scholar
  19. Pietrini P, Dani A, Furey ML, Alexander GE, Freo U, Grady CL, Mentis MJ, Mangot D, Simon EW, Horwitz B, Hazby JV, Schapiro MB (1997) Low glucose metabolism during brain stimulation in older Down’s Syndrome subjects at risk for Alzheimer’s disease prior to dementia. Am J Psychiatry 154: 1063–1069PubMedGoogle Scholar
  20. Schapiro MB, Grady CL, Haxby JV (1992) Nature of mental retardation and dementia in Down’s syndrome: study with PET, CT and neuropsychology. Neurobiol Aging 13: 723–734PubMedCrossRefGoogle Scholar
  21. Schmidt HJ, Schaum U, Pichotka JP (1977) The influence of mode and intensity of homogenization on the absolute value and stability of oxygen consumption of guinea pig liver homogenates. Z Naturforsch 32: 908–912Google Scholar
  22. Seidl R, Greber S, Schuller E, Bernert G, Cairns N, Lubec G (1997) Evidence against increased oxidative DNA damage in Down Syndrome. Neurosci Lett 235: 137–140PubMedCrossRefGoogle Scholar
  23. Tierney MC, Fisher RH, Lewis AJ, Torzitto ML, Snow WG, Reid DW, Nieuwstraaten P, Van Rooijen LAA, Derks HJGM, Van Wijk R, Bischop A (1988) The NINCDA-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer’s disease. Neurology 38: 359–364PubMedCrossRefGoogle Scholar
  24. Vora S, Franke U (1981) Assignment of the human gene for liver-type 6-phosphofruc-tokinase isoenzyme (PFK-L) to chromosome 21 by using somatic cell hybrids and monoclonal anti-L-antibody. Proc Natl Acad Sci USA 78: 3738–3742PubMedCrossRefGoogle Scholar
  25. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol 17: 278–282PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • O. Labudova
    • 1
  • N. Cairns
    • 2
  • E. Kitzmüller
    • 1
  • G. Lubec
    • 1
  1. 1.Department of PediatricsUniversity of ViennaViennaAustria
  2. 2.Institute of PsychiatryBrain BankLondonUK

Personalised recommendations